Published in J Clin Oncol on February 01, 2001
Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci U S A (2007) 4.08
Angiogenesis in rheumatoid arthritis. Arthritis Res (2002) 1.58
Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease. AAPS J (2009) 1.48
The VEGF family in cancer and antibody-based strategies for their inhibition. MAbs (2011) 1.41
Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? Oncologist (2010) 1.27
Anti-VEGF therapies in the clinic. Cold Spring Harb Perspect Med (2012) 1.20
Recombinant human VEGF165b inhibits experimental choroidal neovascularization. Invest Ophthalmol Vis Sci (2010) 1.17
A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma. J Natl Compr Canc Netw (2011) 1.16
Angiogenesis inhibitors in clinical development; where are we now and where are we going? Br J Cancer (2004) 1.15
A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108. Leuk Lymphoma (2009) 1.14
Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov (2016) 1.03
New approaches in angiogenic targeting for colorectal cancer. World J Gastroenterol (2007) 1.03
Present and future evolution of advanced breast cancer therapy. Breast Cancer Res (2010) 1.01
VEGF inhibitors and prostate cancer therapy. Curr Mol Pharmacol (2009) 0.99
Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study. J Clin Oncol (2011) 0.99
Neutralizing type I IFN antibodies trigger an IFN-like response in endothelial cells. J Immunol (2008) 0.98
Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study. Br J Cancer (2009) 0.93
Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer. Oncologist (2012) 0.92
Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer. Invest New Drugs (2002) 0.92
Bevacizumab treatment for advanced breast cancer. Oncologist (2011) 0.90
Bevacizumab for the treatment of glioblastoma. Clin Med Insights Oncol (2013) 0.90
Personalized medicine and treatment approaches in non-small-cell lung carcinoma. Pharmgenomics Pers Med (2012) 0.89
The efficacy of additional bevacizumab to cytotoxic chemotherapy regimens for the treatment of colorectal cancer: an updated meta-analysis for randomized trials. Cancer Biother Radiopharm (2013) 0.88
Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study. World J Gastroenterol (2007) 0.88
Targeting angiogenesis in esophagogastric adenocarcinoma. Oncologist (2011) 0.87
Targeted therapies in the management of renal cell carcinoma: role of bevacizumab. Biologics (2008) 0.84
Application of quantitative pharmacology in development of therapeutic monoclonal antibodies. AAPS J (2010) 0.84
Bevacizumab as a second- or later-line of treatment for metastatic colorectal cancer. World J Gastroenterol (2012) 0.84
Targeted therapies for pancreatic cancer. Br Med Bull (2008) 0.84
Genetic and epigenetic alterations in breast cancer: what are the perspectives for clinical practice? Int J Biochem Cell Biol (2007) 0.82
Targeted therapy of advanced non-small cell lung cancer: the role of bevacizumab. Biologics (2007) 0.80
Evidence for the role of bevacizumab in the treatment of advanced metastatic breast cancer: a review. Breast Cancer (Dove Med Press) (2010) 0.80
The role of anti-angiogenesis in non-small-cell lung cancer: an update. Curr Oncol Rep (2015) 0.79
Monitoring monoclonal antibody delivery in oncology: the example of bevacizumab. PLoS One (2013) 0.78
Bevacizumab in the treatment of HER2-negative breast cancer. Biologics (2008) 0.78
Targeting angiogenesis in advanced cervical cancer. Ther Adv Med Oncol (2014) 0.78
Targeted therapies in the management of colorectal carcinoma: role of bevacizumab. Onco Targets Ther (2009) 0.78
Safety of bevacizumab 7.5 mg/kg infusion over 10 minutes in NSCLC patients. Invest New Drugs (2011) 0.77
Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic. Oncologist (2011) 0.77
First line targeted therapies in breast cancer: focus on bevacizumab. Biologics (2007) 0.76
The future in advanced prostate cancer: take your partners or is the last dance for me? Rev Urol (2004) 0.75
Temporary blood pressure drop after bevacizumab administration is associated with clinical course of advanced colorectal cancer. Br J Cancer (2011) 0.75
Spotlight on bevacizumab in metastatic colorectal cancer: patient selection and perspectives. Gastrointest Cancer (2016) 0.75
Clinical Trials of Antiangiogenesis Therapy in Recurrent/Persistent and Metastatic Cervical Cancer. Oncologist (2016) 0.75
Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation. Target Oncol (2013) 0.75
Bevacizumab: the evidence for its clinical potential in the treatment of nonsmall cell lung cancer. Core Evid (2007) 0.75
Metastatic clear cell carcinoma of the kidney: therapeutic role of bevacizumab. Cancer Manag Res (2010) 0.75
Bevacizumab in the treatment of patients with advanced breast cancer: where have we landed? Ther Adv Med Oncol (2010) 0.75
Phase II study of the Multikinase inhibitor of angiogenesis, Linifanib, in patients with metastatic and refractory colorectal cancer expressing mutated KRAS. Invest New Drugs (2017) 0.75
Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol (2001) 4.97
Minimally important differences were estimated for the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) instrument using a combination of distribution- and anchor-based approaches. J Clin Epidemiol (2005) 4.29
A synthetic IgG-binding domain based on staphylococcal protein A. Protein Eng (1989) 3.31
Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med (1996) 2.86
A novel method for structure-based prediction of ion channel conductance properties. Biophys J (1997) 2.11
Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am (2000) 2.06
Crystal structure of MalK, the ATPase subunit of the trehalose/maltose ABC transporter of the archaeon Thermococcus litoralis. EMBO J (2000) 2.05
MacMolPlt: a graphical user interface for GAMESS. J Mol Graph Model (1998) 2.00
Water in channel-like cavities: structure and dynamics. Biophys J (1996) 1.66
Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma. Cancer (2000) 1.62
Rhizobium meliloti anthranilate synthase gene: cloning, sequence, and expression in Escherichia coli. J Bacteriol (1989) 1.47
Conservation analysis and structure prediction of the SH2 family of phosphotyrosine binding domains. FEBS Lett (1992) 1.45
A gene fusion system for generating antibodies against short peptides. Gene (1987) 1.42
Dementia and the nursing home: association with care needs. J Am Geriatr Soc (1992) 1.39
Boxfishes (Teleostei: Ostraciidae) as a model system for fishes swimming with many fins: kinematics. J Exp Biol (2001) 1.34
Cooperative effects by the initiation codon and its flanking regions on translation initiation. Gene (2001) 1.33
Characterization of a succinate dehydrogenase complex solubilized from the cytoplasmic membrane of Bacillus subtilis with the nonionic detergent Triton X-100. J Bacteriol (1979) 1.29
Prediction by a neural network of outer membrane beta-strand protein topology. Protein Sci (1998) 1.29
Characterization of succinic dehydrogenase mutants of Bacillus subtilis by crossed immunoelectrophoresis. J Bacteriol (1978) 1.27
Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst (2001) 1.26
Simulation studies of alamethicin-bilayer interactions. Biophys J (1997) 1.26
A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection. J Infect Dis (1999) 1.26
The Reaction Level Scale (RLS85). Manual and guidelines. Acta Neurochir (Wien) (1988) 1.24
Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer. Clin Cancer Res (1999) 1.20
From force fields to dynamics: classical and quantal paths. Science (1990) 1.20
The construction and interpretation of MCSCF wavefunctions. Annu Rev Phys Chem (1998) 1.19
Efficient secretion and purification of human insulin-like growth factor I with a gene fusion vector in Staphylococci. Nucleic Acids Res (1985) 1.18
Intrinsic rectification of ion flux in alamethicin channels: studies with an alamethicin dimer. Biophys J (1997) 1.16
High-dose aldesleukin in renal cell carcinoma: long-term survival update. Cancer J Sci Am (1997) 1.15
Health education centers. Their role in medical education. JAMA (1971) 1.14
Role of heme in synthesis and membrane binding of succinic dehydrogenase in Bacillus subtilis. J Bacteriol (1979) 1.14
Engineering stabilized ion channels: covalent dimers of alamethicin. Biochemistry (1996) 1.10
Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons. J Infect Dis (1997) 1.08
A comparison of the Glasgow Coma Scale and the Reaction Level Scale (RLS85). J Neurosurg (1988) 1.05
"Harvey," the cardiology patient simulator: pilot studies on teaching effectiveness. Am J Cardiol (1980) 1.04
Evidence of self-correcting spiral flows in swimming boxfishes. Bioinspir Biomim (2008) 1.02
Co-existing structures of an mRNA stability determinant. The 5' region of the Escherichia coli and Serratia marcescens ompA mRNA. J Mol Biol (1993) 1.02
Interference with nuclear factor kappa B and c-Jun NH2-terminal kinase signaling by TRAF6C small interfering RNA inhibits myeloma cell proliferation and enhances apoptosis. Oncogene (2006) 1.02
Effect of formulation solubility and hygroscopicity on disintegrant efficiency in tablets prepared by wet granulation, in terms of dissolution. J Pharm Sci (1991) 1.00
TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. Circulation (1997) 0.99
An internal affinity-tag for purification and crystallization of the siderophore receptor FhuA, integral outer membrane protein from Escherichia coli K-12. Protein Sci (1998) 0.99
Expression of human insulin-like growth factor I in bacteria: use of optimized gene fusion vectors to facilitate protein purification. Biochemistry (1987) 0.98
Cardiology patient simulator and computer-assisted instruction technologies in bedside teaching. Med Educ (1990) 0.98
The effect of tea consumption on oxidative stress in smokers and nonsmokers. Proc Soc Exp Biol Med (1999) 0.97
Growth factors affecting human thrombocytopoiesis: potential agents for the treatment of thrombocytopenia. Blood (1992) 0.97
Evaluation of the pain suppressive effect of different frequencies of peripheral electrical stimulation in chronic pain conditions. Acta Orthop Scand (1976) 0.97
Effects of cytochalasins B and D on alloxan inhibition of insulin release. Biochem Biophys Res Commun (1975) 0.97
Tissue-specific regulation of rat estrogen receptor mRNAs. Mol Endocrinol (1989) 0.97
Desmoid tumors of the chest wall. A locally recurrent problem. J Thorac Cardiovasc Surg (1992) 0.97
Production of specific antibodies against protein A fusion proteins. EMBO J (1986) 0.97
On acupuncture analgesia and the mechanism of pain. Am J Chin Med (Gard City N Y) (1975) 0.96
A monoclonal IgG anticardiolipin antibody from a patient with the antiphospholipid syndrome is thrombogenic in mice. Proc Natl Acad Sci U S A (1996) 0.96
Molecular modelling of Staphylococcal delta-toxin ion channels by restrained molecular dynamics. Protein Eng (1996) 0.95
Genetic heterogeneity in isogenic homozygous clonal zebrafish. Proc Natl Acad Sci U S A (1995) 0.95
Seven-helix bundles: molecular modeling via restrained molecular dynamics. Biophys J (1995) 0.94
Alternatively spliced exons encode the tissue-specific 5' termini of leukocyte pp52 and stromal cell S37 mRNA isoforms. Genomics (1996) 0.93
Current therapy of cutaneous melanoma. Plast Reconstr Surg (2000) 0.93
Isolation of cDNA sequences coding for a part of human tissue plasminogen activator. Proc Natl Acad Sci U S A (1983) 0.93
The ATPase reaction cycle of yeast DNA topoisomerase II. Slow rates of ATP resynthesis and P(i) release. J Biol Chem (2001) 0.93
A placebo-controlled evaluation of single, escalating doses of CL 284,846, a non-benzodiazepine hypnotic. J Clin Pharmacol (1994) 0.92
Computer modeling of estradiol interactions with the estrogen receptor. J Steroid Biochem (1986) 0.92
Variations in adequate levothyroxine replacement therapy in patients with different causes of hypothyroidism. Endocr Pract (2004) 0.92
A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood (1996) 0.91
Dual affinity fusion approach and its use to express recombinant human insulin-like growth factor II. Proc Natl Acad Sci U S A (1989) 0.91
A recombinant Escherichia coli heat-stable enterotoxin (STa) fusion protein eliciting anti-STa neutralizing antibodies. FEMS Microbiol Lett (1991) 0.90
Bacillus subtilis mutant with temperature-sensitive net synthesis of phosphatidylethanolamine. J Bacteriol (1977) 0.88
Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours. Br J Cancer (2011) 0.88
Synthesis and secretion of a fibrinolytically active tissue-type plasminogen activator variant in Escherichia coli. Gene (1991) 0.88
Myeloid progenitor cell proliferation and mobilization effects of BB10010, a genetically engineered variant of human macrophage inflammatory protein-1alpha, in a phase I clinical trial in patients with relapsed/refractory breast cancer. Blood Cells Mol Dis (1998) 0.87
Inhibition of coagulation by a phosphorothioate oligonucleotide. Antisense Nucleic Acid Drug Dev (1997) 0.87
A large convexity meningioma followed by liquorrhoea from a nasal encephalocele. A case report. Acta Neurochir (Wien) (1981) 0.87
Accurate ab initio potential energy curve of F2. II. Core-valence correlations, relativistic contributions, and long-range interactions. J Chem Phys (2007) 0.87
Cardiology patient simulator. Development of an animated manikin to teach cardiovascular disease. Am J Cardiol (1974) 0.86
Human immunodeficiency viral protease is catalytically active as a fusion protein: characterization of the fusion and native enzymes produced in Escherichia coli. Arch Biochem Biophys (1990) 0.86
The structure of porin from Paracoccus denitrificans at 3.1 A resolution. FEBS Lett (1997) 0.86
Current reporting of responsiveness in acute cerebral disorders. A survey of the neurosurgical literature. J Neurosurg (1988) 0.86
Regulation of tryptophan genes in Rhizobium leguminosarum. J Bacteriol (1982) 0.86
Approaches for improving the stability of ketorolac in powder blends. J Pharm Sci (1995) 0.85
Alamethicin channels in a membrane: molecular dynamics simulations. Faraday Discuss (1998) 0.85
Adoption and integration of simulation-based learning technologies into the curriculum of a UK Undergraduate Education Programme. Med Educ (2003) 0.83
Accurate ab initio potential energy curve of F2. III. The vibration rotation spectrum. J Chem Phys (2007) 0.83
Synthesis of hydroxy and methoxy perylene quinones, their spectroscopic and computational characterization, and their antiviral activity. Photochem Photobiol (2005) 0.83
In vivo administration of recombinant methionyl human stem cell factor expands the number of human marrow hematopoietic stem cells. Blood (1993) 0.83
Nanojets, electrospray, and ion field evaporation: molecular dynamics simulations and laboratory experiments. J Phys Chem A (2008) 0.82
Structure of a combination of Functional Independence Measure and Instrumental Activity Measure items in community-living persons: a study of individuals with cerebral palsy and spina bifida. Arch Phys Med Rehabil (1996) 0.82
Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials. J Clin Oncol (2001) 0.82
Clinical efficacy and safety in head lice infection by Pediculus humanis capitis De Geer (Anoplura: Pediculidae) of a capillary spray containing a silicon-oil complex. Parasite (2010) 0.82
Costimulatory signals can selectively modulate cytokine production by subsets of CD4+ T cells. J Immunol (1995) 0.82
Polyethylene glycol conjugated interleukin-2: clinical and immunologic effects in patients with advanced renal cell carcinoma. Invest New Drugs (1994) 0.82
Dopamine and nonmodulating hypertension. Am J Hypertens (1990) 0.82
Teaching bedside cardiologic examination skills using "Harvey", the cardiology patient simulator. Med Clin North Am (1980) 0.82
Post-operative thromboembolism in neurosurgery. A study on the prophylactic effect of calf muscle stimulation plus dextran compared to low-dose heparin. Acta Neurochir (Wien) (1986) 0.81
Electrically induced atrial tachycardia with block. A therapeutic application of permanent radiofrequency atrial pacing. Circulation (1971) 0.81
Erythropoietin production. A potential marker for interleukin-2/interferon-responsive tumors. Cancer (1993) 0.81
Electro-acupuncture. Effect on pain threshold measured with electrical stimulation of teeth. Brain Res (1973) 0.81